Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
D Jayne, B Rovin, EF Mysler, RA Furie… - Annals of the …, 2022 - ard.bmj.com
Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …
Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval
MF Loncharich, CW Anderson - 2022 - Wiley Online Library
Journal Club Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al.
Anifrolumab, an anti‐interferon‐α receptor monoclonal antibody, in moderate‐to‐severe …
Anifrolumab, an anti‐interferon‐α receptor monoclonal antibody, in moderate‐to‐severe …
[PDF][PDF] Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
[HTML][HTML] Trial of anifrolumab in active systemic lupus erythematosus
Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Y Tanaka, R Tummala - Modern Rheumatology, 2021 - academic.oup.com
Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III …
Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
Long‐term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open‐label extension study
WW Chatham, R Furie, A Saxena… - Arthritis & …, 2021 - Wiley Online Library
Objective To investigate long‐term safety and tolerability of anifrolumab, a human
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …
monoclonal antibody to the type I interferon (IFN) receptor subunit 1, in patients with …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that frequently
affects the kidneys, known as lupus nephritis (LN). Such patients are treated with …
affects the kidneys, known as lupus nephritis (LN). Such patients are treated with …
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral …
MB Condon, D Ashby, RJ Pepper, HT Cook… - Annals of the …, 2013 - ard.bmj.com
Objectives Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus
(SLE). All current treatment regimens include oral steroids, which are associated with severe …
(SLE). All current treatment regimens include oral steroids, which are associated with severe …
相关搜索
- lupus nephritis trial of type
- lupus nephritis mycophenolate mofetil
- anifrolumab efficacy patients with sle
- lupus nephritis oral steroids
- efficacy of anifrolumab lupus erythematosus
- lupus nephritis obinutuzumab for the treatment
- lupus nephritis biological drugs
- lupus nephritis infectious complications
- interferon α lupus erythematosus
- anifrolumab in adults lupus erythematosus